

# Scientific Review Report

The future of high-impact publication is here

[Prepared by our professional reviewer, senior science editor, and managing editor]

Summary

It was a pleasure working on your document. This study on the value of galectin-1, -3, and -7 expression patterns in predicting overall survival in ovarian cancer presented findings that are likely to be of substantial interest to cancer researchers and clinicians. Overall, the title, abstract, and keywords give the readers a good idea of the paper and the methodology applied in the study is adequate to answer the research question. The reporting of the results, however, has several weaknesses with respect to the structure of the section and the description of the findings. I also noted some ambiguities in data presentation in the figures and tables. In addition, analysis related to paired expression of the studied galectins is incomplete. I have made recommendations to help you address these focus areas.

Scientific Review Report

(Click on any section label to go to that section)

[Professional reviewer's comments 3](#_Toc46245031)

[Senior science editor’s comments on language and paper structure 7](#_Toc46245032)

[Senior science editor’s and managing editor’s comments on the paper’s journal readiness 9](#_Toc46245033)

Professional Reviewer's Comments

[Professional Reviewer's Comments 3](#_Toc46245031)

[Senior Science Editor’s Comments on Language and Paper Structure 7](#_Toc46245032)

[Senior Science Editor’s and Managing Editor’s Comments on the Paper’s Journal Readiness 9](#_Toc46245033)

## Major issues (likely to be raised by the journal peer reviewer and cause rejection) and corresponding next steps the author should take.

* One of the aims stated for the study is to investigate whether the expression levels of different galectins are correlated in ovarian cancer” because “there is a critical need for a comprehensive study of various galectins in a representative ovarian cancer panel.” However, you have not evaluated the correlation between combinations of different galectins and the outcome (survival). This aspect of the study needs to be clarified.
* The number of patients does not seem to be justified by power analysis, and it is unclear whether the sample size was sufficient to achieve statistical significance. A power analysis should be performed, and whether it confirmed that the results of the study were statistically conclusive should be indicated.
* There seem to be no control samples, i.e., those from cancer-free individuals. This aspect needs to be addressed in the manuscript.
* Histological groups (serous, endometrioid, clear cell, mucinous) should be briefly characterized, especially with regard to their comparative malignancy.
* Control tissue staining for all galectins should be presented in Fig. 1 and in Table 5.
* The result that “Gal-1 stromal staining serves as an independent prognostic factor for overall survival” has already been obtained in a previous study (Kim et al. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer. 2012 Aug;48(12):1914-21). This fact should be indicated, and the previous study must be appropriately cited.
* The statement that “it is apparently nuclear and not cytoplasmic Gal-3 expression that has a major influence on patients’ outcomes” in lines 260-261 of the Discussion is premature and does not correspond to the facts. Other studies (17, 27) obtained the opposite results both in terms of Gal-3 localization and cancer prognosis, as they showed that cytoplasmic Gal-3 had a negative correlation with cancer prognosis. This statement should be deleted, as you do not present enough evidence for total dismissal of the previous findings. Instead, the reason for this discrepancy between the present and earlier studies should be discussed.
* Correlations between expression patterns of Gal-1, -3, and -7 should be interpreted in view of your own findings regarding the distinct influence of these galectins on survival of ovarian cancer patients, i.e., the fact that nuclear Gal-3 indicates good prognosis and cytoplasmic Gal-1 and -7 indicate poor prognosis, whereas their expression showed positive correlation. Given these data, the statement that “This observation … suggests that galectins might also share common functions in ovarian cancer molecular biology” (lines 286-288 in the Discussion) is not supported by the results, as high expression of Gal-3 inhibits cancer progression, while that of Gal-1 and -7 promotes it, indicating that their functions are far from common in ovarian cancer according to your data.
* The Discussion should serve to emphasize the contribution of the study to the understanding of the prognostic potential of galectins in ovarian cancer. This is currently not the case; you should add a few lines to highlight this.

## Minor issues (likely to be raised by the journal peer reviewer for consideration but not cause rejection) and corresponding next steps the author should take.

* The Introduction does not provide a sufficient background of the problem studied. Mechanisms underlying the oncogenic effects of galectins should be outlined in view of their localization. Distinct functional activities of galectins in intracellular compartments should also be presented and appropriate references must be cited.
* The information not relevant to the study, such as Gal oligomerization or the number of CRD domains (lines 40-45 in the Introduction), should be removed.
* The Results section is not appropriately organized, and the presentation of data does not correspond to the data structure in the illustrations. As a rule, the data shown in a single illustration should be described in the same paragraph. However, the Results are structured according to individual galectins, and certain illustrations present the data related to all studied galectins (Fig. 1 – IF results; Fig. 2 – Survival; Table 2 - Multivariate analysis of prognostic factors), which complicates comparative analysis of the data and decreases the coherence and readability of the text.

## Does the paper present novel ideas/a novel direction with regard to the field of research?

In clearly stating the gaps in the existing literature on the topic of your study and presenting the rationale for your study, you have established the novelty of the study in the Introduction section. However, the novelty of the study should also be discussed in the abstract. It should also be highlighted in the Discussion by stating how the study furthered understanding of the prognostic value of the investigated galectins in ovarian cancer.

## Does the paper present novel ideas or build on the research published in the target journal?

Yes, the paper presents novel ideas regarding the importance of galectin-1, -3, and -7 expression patterns in predicting overall survival in ovarian cancer.

## Is the research rationale sound? (is the reason for conducting the research explained clearly in the paper?)

The study rationale is discussed to some extent. The rationale for studying the effect of galectins on survival in ovarian cancer depending on their cellular localization should be elaborated. Moreover, the second aim stated for the study is to investigate whether the expression levels of different galectins are correlated in ovarian cancer because “there is a critical need for a comprehensive study of various galectins in a representative ovarian cancer panel.” The purpose of this analysis is unclear, as you have not evaluated the correlation between combinations of different galectins and the outcome (survival).

## Is the literature review complete? Which other papers can the author cite?

The literature review is not complete. The biological functions of galectins related to tumorigenesis, including malignant transformation, invasion, and metastasis, are not described, and it is unclear how galectins are involved in all these processes. As the study specifically focused on the correlation of galectin expression in different cellular compartments (extracellular, cytoplasmic, and nuclear) with ovarian cancer, you should include an outline of localization-dependent functional activity of galectins. Thus, it should be indicated that extracellular galectins mediate cell–cell and cell–ECM contacts via binding to mucins, including cancer antigen 125, which promotes tumor cell adhesion, migration, and invasion. Through interaction with glycosylated cell surface receptors, galectins induce the expression of oncogenes, thereby promoting cell proliferation. In contrast, intracellular galectins regulate signaling pathways and gene transcription by interacting with cytoplasmic and nuclear proteins. Consider citing the following papers along with presenting this information:

* Funasaka et al. Nuclear transport of galectin-3 and its therapeutic implications. Semin Cancer Biol. 2014 Aug; 0: 30–38.
* Bhat et al. Nuclear repartitioning of galectin-1 by an extracellular glycan switch regulates mammary morphogenesis. Proc Natl Acad Sci U S A. 2016 Aug 16; 113(33): E4820–E4827.
* Patterson et al. Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus. Glycoconj J. 2002; 19(7-9): 499–506.

## Are the research implications clearly mentioned? If they are mentioned, are they sound? If they are not mentioned, what tips should the author follow?

The implications of the results in the context of ovarian cancer are appropriately described in the Discussion section. However, as Scientific Reports caters to a broad audience, I recommend including any additional implications of your findings for other fields of research. For example, it appears that galectins have been implicated in a broad range of pathological conditions such as inflammation and fibrosis. A brief mention of these in the Discussion or Conclusions sections would, therefore, improve the multidisciplinary appeal of your manuscript.

## Are the concluding statements clear, and do they mention the contributions, limitations, and next steps for other researchers in the field?

A clear Conclusion section is provided. However, it can better emphasize the contribution of this study to the prognostic potential of galectins in ovarian cancer. Moreover, the limitations of the study need to be listed at the end of the Discussion before the scope for further research in the field is discussed.

## Is the research design appropriate? What are the gaps, and what should be done to fill these gaps?

Overall, the study design is appropriate. There are two major potential issues with the design as currently reported. First, the number of patients does not seem to be justified by a power analysis, and it is unclear whether the sample size was sufficient to achieve statistical significance. A power analysis should be performed, and whether it confirmed that the results of the study were statistically conclusive should be indicated. Second, there were no control samples, i.e., samples from cancer-free individuals. This also needs to be addressed in the manuscript. Finally, the correlation between different combinations of galectins and survival should be analyzed.

## Is the research methodology sound and relevant to the field?

Overall, the methodology applied in the study is adequate to answer the research question. The two points mentioned above should be addressed to ensure that the reporting of the methodology is without errors. The histological groups (serous, endometrioid, clear cell, mucinous) should also be briefly characterized, especially with regard to their comparative malignancy.

## Does the data appear accurate, and has it been interpreted appropriately? Flag cases of insufficient or insignificant data with the author.

* The Results should be restructured. First, IF data should be presented and interpreted for all galectins (Fig. 1). Second, each galectin should be described for its correlations with clinical and pathological factors (Tables 1, 3, and 4), and compared. Third, overall survival depending on galectin expression (Fig. 2) should be presented. Fourth, multivariate analysis of prognostic factors for overall survival in ovarian cancer (Table 2) should be analyzed. Finally, correlations among galectin expression patterns (Table 5) should be described.
* In Fig. 1, nuclear and cytoplasmic staining for Gal-3 and -7 is not clearly visible and should be indicated by arrows or asterisks.
* In Table 1, the last line (≤ 60) should be changed to > 60.
* It is unclear what statistical significance (*p*-value) is related to in Histology (Tables 1, 3, and 4). There are four histological tumor types in these tables and three levels of expression (negative, low, and high) in Table 4, but only one p-value is shown, and it is unclear which groups were compared. It should be clearly indicated in the column (*p* versus …) or in a footnote to each table.
* The purpose of performing the analysis presented in Table 5 is unclear, as correlations between galectin expression patterns and their significance in ovarian cancer are not interpreted. Nuclear Gal-3 correlated with cytoplasmic Gal-1 and -7; however, nuclear Gal-3 indicated good prognosis, whereas cytoplasmic Gal-1 and -7 indicated poor prognosis. Please explain this contradiction. Did any of the galectin combinations presented in Table 5 correlate with patient survival? What were such combinations in normal control samples? These issues must be addressed.

## Should the author get their data verified by a statistician or submit analyzed datasets to the journal?

Further data verification and submission are not required. However, the journal does require a Data Availability Statement to be included in the Methods section of submitted manuscripts, and this should be added.

1. **Does the journal accept this article type?**

*Scientific Reports* publishes original research in only one format: Article. This manuscript is an original research article and follows the journal-recommended structure for articles.

## Does the research in this article lie within the target journal’s scope?

*Scientific Reports* caters to a broad scientific audience and welcomes research from all areas across the natural and clinical sciences. Your paper will definitely fit this broad scope.

Senior Science Editor’s Comments on  
Language and Paper Structure

[Peer Reviewer's Comments 3](#_Toc46245031)

[Senior Science Editor’s Comments on Language and Paper Structure 7](#_Toc46245032)

[Senior Science Editor’s and Managing Editor’s Comments on the Paper’s Journal Readiness 9](#_Toc46245033)

## How was the paper's overall language quality prior to editing?

The language of the manuscript needed several improvements to make it submission-ready. Changes were made to correct grammatical errors related to article use, to improve word choice and sentence construction, and to ensure the use of formal language.

## What were the top 3 recurring grammar and language issues found and edited for native tone?

1. Poor article use: Definite and indefinite articles were added wherever missing in the file. Editorial changes made in this regard are presented in boldface in the following examples.

* According to our data, Gal-1 staining in **the** cytoplasm and stroma… (Body parts are one-of-a-kind entities and their names are preceded by the definite article)
* Recently, **the** carbohydrate stem cell marker TF1 has been proposed as **a** negative prognostic marker in ovarian cancer displaying wild-type p53… (Specific, countable nouns take the definite article and non-specific, countable nouns take the indefinite article)

2. Word choice: “also” at the start of a sentence was replaced with the more formal alternative “In addition.” In a few instances, terms were replaced with more appropriate alternatives based on the context. For example, “reduced outcomes” was changed to “poorer outcomes.”

3. Sentence construction: The intended meaning did not come through very clearly in some sentences. For example, “However, it requires further investigations to explain cases without Gal-1 expression in cancer cells but in the stroma or vice versa” was changed to “However, further investigations are required to explain cases of Gal-1 expression in the stroma but not in cancer cells, and vice versa.”

## Does the paper adhere to the target journal's language preference?

The journal prefers British English usage. The manuscript has been edited accordingly. The journal also asks authors to avoid the use of technical jargon without it being explained. The manuscript meets this requirement.

## Do the main ideas in the paper flow well? Was the flow of ideas/the main argument natural?

The flow of ideas in the paper was appropriate for the most part and relevant information was provided under each section. The results section needs reorganization as explained earlier.

## What types of changes were made for improvements to paper flow and how has the paper's readability improved because of these?

A concluding statement was added to the abstract. Since the Discussion should ideally begin with a summary of the main aims and findings of the study to improve the flow of ideas from the Results, a statement to this effect was added. Finally, the Conclusions section should ideally follow the Discussion section. This has, thus, been moved from after the Methods to after the Discussion.

## Does the target journal have a word count limit, and does the paper adhere to this limit after editing?

The title is within the 20-word limit. The target journal requires the abstract to be within 200 words; the edited abstract adheres to this limit. Finally, the main text is required to be no more than 4,500 words (not including Abstract, Methods, References and figure legends). This limit has also been met.

## List out all the author preferences and instructions that could not be followed and why.

All author preferences and instructions have been followed.

## What were the major formatting requirements of the journal for this paper, and what changes have been made to meet these requirements?

* The journal requires the author names, affiliations, and contact information to be included on the title page with the corresponding author indicated with an asterisk. Placeholders have been created for this information.
* Keywords are not requested by the journal, so these have been removed.
* The journal does not require sections to be numbered, so section numbering was eliminated in the manuscript.
* In-text citations were to be in the form of sequential superscript numbers. They have been formatted to comply with this requirement.
* Figure callouts are to be mentioned using the abbreviation Fig. except at the start of a sentence. This change has been made in all relevant instances.

Senior Science Editor’s and Managing Editor’s Comments on the Paper’s Journal Readiness

[Peer Reviewer's Comments 3](#_Toc46245031)

[Senior Science Editor’s Comments on Language and Paper Structure 7](#_Toc46245032)

[Senior Science Editor’s and Managing Editor’s Comments on the Paper’s Journal Readiness 9](#_Toc46245033)

## What details or documents are missing in the paper submission package based on the target journal's formatting and submission requirements?

The journal requires a separate cover letter to be provided with the submission, and one has been created for you. In the manuscript itself, please remember to add the author information on the title page and the reference list. A Data Availability Statement must be included at the end of the main text, before the References.

## Does the paper need to be split for submission?

Typically, the journal requires individual figure files. However, for first submissions (i.e. not revised manuscripts), you may incorporate the manuscript text and figures into a single file up to 3 MB in size in either a Microsoft Word, LaTeX, or PDF format. Since your manuscript is a first submission, it does not need to be split.

## Does the paper need to be blinded for review, and has it been blinded?

The paper does not need to be blinded for review.

## Have all the formatting guidelines, including the right file format for submission, been addressed? Mention any that have not and why they have not been addressed.

The paper is currently in MS Word format, which is one of the accepted file formats (the journal accepts either a Microsoft Word, LaTeX, or PDF format).

* The format for author information could not be checked, as this was not provided. Placeholders with instructions have been added on the title page.
* References could not be formatted, as these are not provided for editing.
* Tables need to be converted into an editable format. This was not done as file type conversion is beyond the scope of the service.

## Have ethical and financial declarations been provided? If not, alert the author to do so and explain why.

Ethical and financial declarations have been provided.

## Is a conflict of interest statement provided? If not, alert the author to do so and explain why.

A conflict of interest statement has been provided.

## Has a data availability statement been provided? If not, alert the author to do so and explain why.

A data availability statement has not been provided. As per journal guidelines, you must include a Data Availability Statement in all submitted manuscripts (at the end of the main text, before the References section). Data availability statements should include, where applicable, accession codes, other unique identifiers and associated web links for publicly available datasets, and any conditions for access of non-publicly available datasets. Where figure source data are provided, statements confirming this should be included in data availability statements. Please refer to <https://www.nature.com/srep/journal-policies/editorial-policies#availability> for examples of such statements.

## Has the corresponding author been identified for journal interaction?

The corresponding author has not been identified. Placeholders for author information have been added on the title page.

## Are all the references, tables, and figures present?

The references have not been provided for editing. All figures and tables are present.

## Are the references in the right format and the figures and tables labelled appropriately?

* The references have not been provided. Please ensure that a reference list is provided and formatted per the requirements of the target journal. These are the following formats that you should be aware of for different types of references:

**Published papers**

Printed journals

Schott, D. H., Collins, R. N. & Bretscher, A. Secretory vesicle transport velocity in living cells depends on the myosin V lever arm length. J. Cell Biol. 156, 35-39 (2002).

Online only

Bellin, D. L. et al. Electrochemical camera chip for simultaneous imaging of multiple metabolites in biofilms. Nat. Commun. 7, 10535; 10.1038/ncomms10535 (2016).

For papers with more than five authors include only the first author’s name followed by ‘et al.’.

**Books**

Smith, J. Syntax of referencing in How to reference books (ed. Smith, S.) 180-181 (Macmillan, 2013).

**Online material**

Manaster, J. Sloth squeak. Scientific American Blog Network http://blogs.scientificamerican.com/psi-vid/2014/04/09/sloth-squeak (2014).

Hao, Z., AghaKouchak, A., Nakhjiri, N. & Farahmand, A. Global integrated drought monitoring and prediction system (GIDMaPS) data sets. figshare http://dx.doi.org/10.6084/m9.figshare.853801 (2014).

* The figure callouts have been edited to be in the right format. Figure legends are within 350 words.
* Table callouts have been edited to be appropriate. The tables must be submitted in an editable format (Word or TeX/LaTeX, as appropriate), and not as images.